Novartis plans to pursue more bolt-on acquisitions to enhance its portfolio, with a continued focus on strategic therapeutic areas including oncology, immunology, neuroscience, and cardiovascular and renal medicine. CEO Vasant Narasimhan emphasized that the company is actively seeking opportunities that align with its core interests and has the capital to support such deals. Recent acquisitions include U.S. biotech firm Avidity Biosciences for approximately $12 billion and Regulus Therapeutics for up to $1.7 billion, aimed at addressing upcoming patent expirations of key drugs. The company remains committed to dealing in external innovations that create value, particularly in oncology and radioligand therapies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.globalbankingandfinance.com/novartis-eyes-bolt-on-acquisitions-ceo/
